Hepatic Venoocclusive Disease with ImmunodeficiencySymptoms, Doctors, Treatments, Advances & More
Learn About Hepatic Venoocclusive Disease with Immunodeficiency
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
Paul Richardson is a Hematologist Oncology specialist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft. Dr. Richardson is board certified in Medical Oncology.
Dana-Farber Cancer Institute
Robert Soiffer is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Soiffer is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Hepatic Venoocclusive Disease with Immunodeficiency, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Graft.
Dana-Farber Cancer Institute
Joseph Antin is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Antin is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Hepatic Venoocclusive Disease with Immunodeficiency, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.
Summary: This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses o...
Summary: This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.